Loading
Loading
Organ & Bioregulator Research · 20mg
Janoshik-tested · 10 vials per kit
Prostamax is a synthetic tetrapeptide bioregulator studied in preclinical research for its prostate-targeted effects. Research has examined its potential to improve lower urinary tract symptoms associated with benign prostatic hyperplasia, alleviate prostatic inflammation, promote prostate tissue regeneration, and delay degenerative changes. Studies have also explored anti-inflammatory, anti-aging, and hormone-regulatory properties.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Chemical Properties
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
Prostamax
Prostamax is a synthetic tetrapeptide developed as a prostate bioregulator in the Khavinson series. It is studied for regulatory effects on prostatic epithelial and stromal cells, particularly relevant to age-related prostatic hypertrophy and urinary dysfunction.
Chromatin-binding mechanisms are proposed to regulate gene expression in prostate epithelial cells, potentially influencing androgen receptor signalling pathways, PSA production, and the balance between cell proliferation and apoptosis relevant to prostate health.
Preclinical research includes benign prostatic hyperplasia models and age-related prostate function decline. Some Russian clinical observations describe improvements in prostate volume and urinary symptom scores in men with early BPH treated with Prostamax as part of comprehensive bioregulator protocols.
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
